Skip to main content
A

ALTERITY THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · ATH ISIN · AU0000043945 LEI · 52990045JUZVZ9QL3159 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,312 across all filing types
Latest filing 2026-04-26 Regulatory Filings
Country AU Australia
Listing ASX ATH

About ALTERITY THERAPEUTICS LIMITED

https://alteritytx.com/

Alterity Therapeutics Limited is a clinical-stage company focused on developing disease-modifying therapies for neurodegenerative disorders. The company's research and development efforts center on addressing the underlying pathology of conditions such as Multiple System Atrophy (MSA) and Parkinson's disease. Its lead therapeutic candidate, ATH434, is an orally administered small molecule designed to redistribute excess iron in the brain, thereby inhibiting the aggregation of alpha-synuclein and reducing oxidative stress. By targeting these specific mechanisms, the company aims to preserve neuronal integrity and slow the progression of parkinsonian diseases. Alterity utilizes a specialized platform to identify compounds that modulate metal-protein interactions, focusing on first-in-class treatments for orphan diseases with high unmet medical needs.

Recent filings

Filing Released Lang Actions
Alterity Receives Positive FDA Feedback on CMC Meeting 3 pages 189.7KB
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing positive FDA feedback from a Type C meeting related to the company’s drug development program. It does not present financial results, dividend details, M&A activity, governance materials, or any of the more specific categories. It’s a general regulatory update and thus falls into the fallback category for miscellaneous regulatory filings. Therefore, the appropriate classification is RNS.
2026-04-26 English
Change in substantial holding 6 pages 351.8KB
Major Shareholding Notification Classification · 1% confidence The document is a Form 604 “Notice of change of interests of substantial holder” filed under the Australian Corporations Act, detailing the Bank of New York Mellon’s and its group entities’ changes in relevant shareholdings and voting power. This is a statutory notification of changes in significant share ownership levels (crossing thresholds), matching the Major Shareholding Notification category (MRQ).
2026-04-23 English
Alterity Presents New Analysis of ATH434 Phase 2 Data at AAN 4 pages 228.0KB
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing new Phase 2 clinical trial data presented at a scientific conference. It is not an annual or interim financial report, earnings release, management change, proxy, or dividend notice. It does not attach the full report but simply summarizes and directs readers to the presentation on the company website. This type of general corporate announcement falls under the fallback category for miscellaneous regulatory filings.
2026-04-21 English
Initial Director's Interest Notice - Cunningham 2 pages 251.2KB
Director's Dealing Classification · 1% confidence The document is an ASX Appendix 3X “Initial Director’s Interest Notice” under listing rule 3.19A.1, which reports a company director’s personal interests (or nil interests) in securities. This matches our category for insider share-related notifications by directors. Therefore, it is a Director’s Dealing (DIRS).
2026-04-20 English
Notification regarding unquoted securities - ATH 8 pages 21.9KB
Share Issue/Capital Change Classification · 1% confidence The document is an ASX ‘Appendix 3G’ form notifying the issue of unquoted equity securities (employee options). It details a new class of unlisted options, exercise price, expiry, total issued, and complies with ASX listing rule requirements for capital changes. This is a share issuance/capital change announcement, matching the Share Issue/Capital Change category (SHA).
2026-04-19 English
Notification regarding unquoted securities - ATH 8 pages 21.9KB
Share Issue/Capital Change Classification · 1% confidence The document is an ASX Appendix 3G form notifying the issue of unquoted equity securities (employee options). It provides details of a new class of unquoted options issued under an employee incentive scheme, the number issued, exercise price, expiry, and ASX listing rule exceptions. This is an announcement of a new share issue/capital change rather than a full report or financial statement. Therefore it falls under Share Issue/Capital Change (SHA).
2026-04-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.